This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hagens Berman Investigates Accretive Health, Inc., Notifies Investors Of Case Deadline

CHICAGO, May 1, 2012 /PRNewswire/ -- Hagens Berman today announced that it is investigating Accretive Health Inc. (NYSE: AH) ("Accretive Health") following the release of a report by the Minnesota Attorney General questioning certain practices used by the company.

Investors who purchased or otherwise acquired shares of Accretive Health common stock between March 2, 2011 and April 24, 2012 (the "Class Period"), and who suffered losses are encouraged to contact Hagens Berman Partner Reed Kathrein. Mr. Kathrein is leading Hagens Berman's investigation and can be reached at (510) 725-3000. Investors may also contact the firm via email at or by visiting

On Jan. 19, 2012, Minnesota's Attorney General filed a lawsuit alleging that Accretive Health violated privacy laws following the theft of a laptop containing patient data.

On March 29, 2012, the company announced that in an effort to resolve the allegations and underlying issues, it would no longer collect debts for Fairview Health Services. The company announced that this shift would have a revenue impact "in the range of $62 million to $68 million, or approximately 6% of the company's expected 2012 revenue."

Following the announcement, the share price of Accretive Health common stock fell nearly 19 percent.

The stock price fell again on April 25, 2012, this time nearly 41 percent, following the April 24, 2012 release of a report by the Minnesota Attorney General which outlined a number of aggressive practices used by Accretive Health, including stationing debt collectors in emergency rooms.

Hagens Berman's investigation centers around claims that Accretive Health may have failed to disclose material information to investors regarding these allegations during the Class Period. The firm is investigating whether failure to disclose information may have caused the stock price to trade at an artificially high price during the class period.

"We are trying to determine whether Accretive Health knew about violations of privacy laws, but tried to conceal that information from investors," said Mr. Kathrein. "If the company tried to sweep these issues under the rug so as not to damage the share price, investors are entitled to compensation for their losses."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs